LMX-C1Q: A NEW RELIABLE VIRTUAL CROSSMATCH ASSAY TO PREDICT FINAL CROSSMATCH

摘要

Virtual crossmatch (VXM) is being increasingly used for predicting the final XM since the development of sensitive solid phase HLA antibody (HLA-Ab) detection systems. The traditional CDC test is much less sensitive and specific and cannot be used for VXM. Although the Luminex HLA-Ab assay (LMX-IgG) has high sensitivity, it detects non-complement fixing Ab (Non-CFAb) which have not been proven to be clinically relevant. Hence it may exclude potentially compatible donors. The correlation of the new solid phase Luminex C1q assay (LMX-C1q) developed in our laboratory for VXM was evaluated by comparison with crossmatches (both VXM and actual XM) from CAP sample survey reports.